Market Research Logo

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

Summary

Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal (GI) disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional GI disorder. IBS is sub-classified according to the predominant bowel habits. These sub-classifications are constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), mixed-presentation IBS (IBS-M), and unsubtyped IBS (IBS-U).

In the 7MM, the diagnosed prevalent cases of IBS will increase from about 24 million cases in 2016 to around 25 million cases in 2026, at an Annual Growth Rate (AGR) of about 0.3% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and UK), the diagnosed prevalent cases of IBS will increase from around 9 million cases in 2016 to about 9.3 million cases in 2026, at an AGR of around 0.2%.

Italy had the highest age-standardized diagnosed prevalence of IBS in both men (almost 5%) and women (around 10%) in the 7MM. Spain had the lowest age-standardized diagnosed prevalence of IBS in men (nearly 0.9%) and women (around 2%). The difference in the age-standardized diagnosed prevalence of IBS between men and women was the highest in Italy, atover 5% greater in women than in men. Germany had the lowest difference in the age-standardized prevalence of IBS between men and women, at almost 0.8%.

The report EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026, provides an overview of the risk factors, comorbidities, and global trends for IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS. This report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of IBS segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]) in these markets.

Scope

  • The Irritable bowel syndrome (IBS) EpiCast Report provides an overview of the risk factors and global trends of IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for the total and the diagnosed prevalent cases of IBS. Diagnosed prevalent cases are segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]), and comorbid conditions (anxiety and depression).
  • The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The IBS EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IBS therapeutics in each of the markets covered.
  • Understand magnitude of IBS population by disease type and comorbidities.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Irritable Bowel Syndrome: Executive Summary
2.1 Related Reports
2.2 Upcoming Related Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for IBS (2016-2026)
3.5.1 Total Prevalent Cases of IBS
3.5.2 Diagnosed Prevalent Cases of IBS
3.5.3 Age-Specific Diagnosed Prevalent Cases of IBS
3.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS
3.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtypes
3.5.6 Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for IBS
Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies
Table 3: 7MM, Total Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026
Table 4: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026
Table 5: 7MM, Diagnosed Prevalent Cases of IBS by Clinical Subtypes, Both Sexes, Ages ≥18 Years, N, 2016
Table 6: 7MM, Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity, Both Sexes, Ages ≥18 Years, N, 2016
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of IBS, Ages ≥18 Years, 2016
Figure 3: 7MM, Sources Used and Not Used, Total Prevalent Cases of IBS
Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS
Figure 5: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS Clinical Subtypes
Figure 6: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS With Comorbidity
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report